Transforming breast cancer care

What is OncoMasTR?

OncoMasTR is an exciting new prognostic assay for early stage breast cancer. It will help clinicians and patients to make accurate, informed choices about treatment. 




OncoMasTR is currently being developed by OncoMark Ltd, an Irish diagnostics company.

OncoMasTR works by measuring the expression of certain genes in breast cancer tissue and generates a Yes/No answer to the question of whether a patient would benefit from chemotherapy.